Workshop B: Enhancing Market & Patient Access to Novel CKD Therapies Amongst a Growing Treatment Landscape

Demonstrating value to payors over existing treatments; overcoming systemic barriers to adoption, from shifting nephrology’s focus beyond dialysis to embedding education at centers of excellence, to navigating payer expectations and addressing inequities in patient access.

Key Objectives:

• Identifying barriers to adoption of novel CKD therapies across payer systems and clinical practice
• Leveraging centers of excellence and global nephrology networks (e.g., GlomCon, ISG, ISN) to accelerate HCP education and patient access
• Exploring payor and HTA perspectives on value-based pricing, reimbursement restrictions, and trial comparators
• Addressing disparities in access, mistrust, and underrepresentation of minorities, women, and children in CKD care
• Defining how early detection, tolerability, and patient education can shape real-world uptake of CKD treatments

Speakers:

Daniel Weiner

Professor of Medicine

Tufts Medical Center

Doug Paul

Board Member

NephKey

Leah Conley

Senior Vice President, Patient Access

Travere Therapeutics